atomoxetine hydrochloride has been researched along with Pervasive Child Development Disorders in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 16 (84.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bloch, MH; Reichow, B; Volkmar, FR | 1 |
| Buitelaar, JK; Harfterkamp, M; Hoekstra, PJ; Minderaa, RB; van de Loo-Neus, G; van der Gaag, RJ | 2 |
| Calleja-Pérez, B; Fernández-Jaén, A; Fernández-Perrone, AL; López-Arribas, S; Martín Fernández-Mayoralas, D; Muñoz-Jareño, N | 1 |
| Dalsgaard, S; Nielsen, HS; Simonsen, M | 1 |
| Althaus, M; Buitelaar, JK; de Ruiter, SW; de Sonneville, LM; Donders, AR; Harfterkamp, M; Hoekstra, PJ; Rommelse, NN; van de Loo-Neus, G; van der Meer, JM | 1 |
| Ishizaki, A; Sugama, M | 1 |
| Aman, MG; Arnold, LE; Corbett-Dick, P; Handen, B; Hollway, JA; Hyman, SL; Lecavalier, L; Levato, L; Mendoza-Burcham, M; Mruzek, DW; Pan, X; Silverman, LB; Smith, T; Tumuluru, R | 1 |
| Findling, RL; Rowles, BM | 1 |
| Gjevik, E; Weidle, B; Zeiner, P | 1 |
| Banaschewski, T; Holtmann, M; Poustka, L | 1 |
| Handen, BL; Taylor, J; Tumuluru, R | 1 |
| Calleja-Pérez, B; Campos Díaz, Mdel R; Fernández-Jaén, A; Fernández-Mayoralas, DM; López-Arribas, S; Muñoz-Jareño, N | 1 |
| Buitelaar, JK; Escobar, R; Harfterkamp, M; Hoekstra, PJ; Minderaa, RB; Pamulapati, S; Schacht, A; van de Loo-Neus, G; van der Gaag, RJ | 1 |
| Bhatti, I; Cook-Wiens, G; Gaffney, GR; Hellings, JA; Smith, PO; Thome, A; Yeh, HW | 1 |
| Handen, BL; Hardan, AY; Jou, RJ | 1 |
| Maynard, M; McDougle, CJ; Posey, DJ; Stigler, KA; Wiegand, RE; Wilkerson, J | 1 |
| Buitelaar, JK; Hoekstra, PJ; Kalverdijk, LJ; Minderaa, RB; Steenhuis, MP; Troost, PW; Tuynman-Qua, HG | 1 |
6 review(s) available for atomoxetine hydrochloride and Pervasive Child Development Disorders
| Article | Year |
|---|---|
Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Child, Preschool; Double-Blind Method; Female; Humans; Methylphenidate; Propylamines; Randomized Controlled Trials as Topic | 2013 |
[Autism and attention deficit hyperactivity disorder: pharmacological intervention].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Clonidine; Dopamine Uptake Inhibitors; Drug Evaluation; Guanfacine; Humans; Methylphenidate; Neuroimaging; Propylamines; Psychotropic Drugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
A review of atomoxetine effects in young people with developmental disabilities.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child Development Disorders, Pervasive; Developmental Disabilities; Humans; Propylamines | 2014 |
Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders.
Topics: Adolescent; Amphetamines; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Child, Preschool; Clinical Trials as Topic; Clonidine; Comorbidity; Developmental Disabilities; Drug Therapy, Combination; Female; Fetal Alcohol Spectrum Disorders; Humans; Intellectual Disability; Male; Methylphenidate; Pregnancy; Propylamines; Psychotropic Drugs | 2010 |
[Autism and ADHD across the life span. Differential diagnoses or comorbidity?].
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Comorbidity; Diagnosis, Differential; Humans; Propylamines; Risperidone | 2011 |
Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Clinical Trials as Topic; Humans; Propylamines | 2011 |
5 trial(s) available for atomoxetine hydrochloride and Pervasive Child Development Disorders
| Article | Year |
|---|---|
Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Double-Blind Method; Female; Humans; Male; Propylamines; Psychiatric Status Rating Scales; Time Factors | 2013 |
A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Double-Blind Method; Female; Humans; Male; Propylamines; Treatment Outcome | 2013 |
Atomoxetine in autism spectrum disorder: no effects on social functioning; some beneficial effects on stereotyped behaviors, inappropriate speech, and fear of change.
Topics: Adolescent; Atomoxetine Hydrochloride; Child; Child Development Disorders, Pervasive; Double-Blind Method; Fear; Female; Humans; Male; Propylamines; Social Behavior; Speech; Stereotyped Behavior | 2014 |
Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: a prospective, open-label study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Child, Preschool; Comorbidity; Humans; Male; Neuropsychological Tests; Pilot Projects; Propylamines; Prospective Studies; Time Factors; Treatment Outcome | 2013 |
A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Comorbidity; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Personality Assessment; Propylamines; Psychometrics | 2012 |
8 other study(ies) available for atomoxetine hydrochloride and Pervasive Child Development Disorders
| Article | Year |
|---|---|
Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish registe
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Denmark; Dextroamphetamine; Female; Humans; Male; Mental Disorders; Methylphenidate; Practice Patterns, Physicians'; Prevalence; Propylamines; Registries | 2013 |
[Drug therapy for AD/HD investigation of usefulness of extended-release methylphenidate and atomoxetine from the viewpoint of persistency rate].
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Drug Therapy, Combination; Female; Humans; Male; Methylphenidate; Propylamines; Treatment Outcome; Young Adult | 2014 |
Academy of Medicine Singapore-Ministry of Health clinical practice guidelines: Autism Spectrum Disorders in pre-school children.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Benzodiazepines; Central Nervous System Stimulants; Child Development Disorders, Pervasive; Child, Preschool; Dopamine Antagonists; Humans; Mass Screening; Methylphenidate; Olanzapine; Prognosis; Propylamines; Risperidone; Selective Serotonin Reuptake Inhibitors; Singapore | 2010 |
Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Diagnostic and Statistical Manual of Mental Disorders; Health Status Indicators; Humans; Male; Norway; Outpatients; Propylamines; Prospective Studies; Psychometrics; Sex Factors; Statistics, Nonparametric; Treatment Outcome | 2011 |
A retrospective study of amitriptyline in youth with autism spectrum disorders.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Amitriptyline; Atomoxetine Hydrochloride; Child; Child Development Disorders, Pervasive; Child, Preschool; Female; Humans; Male; Propylamines; Retreatment; Retrospective Studies; Treatment Outcome | 2013 |
Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Child; Child Development Disorders, Pervasive; Female; Humans; Male; Propylamines; Retrospective Studies | 2005 |
Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Asperger Syndrome; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Body Weight; Child; Child Development Disorders, Pervasive; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intelligence; Irritable Mood; Male; Neuropsychological Tests; Pilot Projects; Propylamines; Prospective Studies; Treatment Outcome | 2006 |
Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Development Disorders, Pervasive; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Impulsive Behavior; Male; Personality Assessment; Pilot Projects; Propylamines; Treatment Outcome | 2006 |